157 related articles for article (PubMed ID: 27055285)
41. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
[TBL] [Abstract][Full Text] [Related]
42. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
Thor AD; Liu S; Edgerton S; Moore D; Kasowitz KM; Benz CC; Stern DF; DiGiovanna MP
J Clin Oncol; 2000 Sep; 18(18):3230-9. PubMed ID: 10986055
[TBL] [Abstract][Full Text] [Related]
43. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
Michaelidou K; Ardavanis A; Scorilas A
Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
[TBL] [Abstract][Full Text] [Related]
44. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
45. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
46. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
47. EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.
Chan E; Alkhasawneh A; Duckworth LV; Aijaz T; Toro TZ; Lu X; Hughes SJ; Collinsworth A; George TJ
J Gastrointest Oncol; 2016 Dec; 7(6):838-847. PubMed ID: 28078108
[TBL] [Abstract][Full Text] [Related]
48. Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.
Xu J; Yang W; Wang Q; Zhang Q; Li X; Lin X; Liu X; Qin Y
Int J Clin Exp Pathol; 2014; 7(11):7915-22. PubMed ID: 25550832
[TBL] [Abstract][Full Text] [Related]
49. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
50. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
Constantinou C; Papadopoulos S; Karyda E; Alexopoulos A; Agnanti N; Batistatou A; Harisis H
In Vivo; 2018; 32(2):303-311. PubMed ID: 29475913
[TBL] [Abstract][Full Text] [Related]
51. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
52. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
53. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
54. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers.
Lee J; Kim S; Kim P; Liu X; Lee T; Kim KM; Do IG; Park JO; Park SH; Jang J; Hoe N; Harvie G; Kuller A; Jain A; Meyer G; Leesman G; Park YS; Choi MG; Sohn TS; Bae JM; Lim HY; Singh S; Kang WK
PLoS One; 2013; 8(1):e54644. PubMed ID: 23372746
[TBL] [Abstract][Full Text] [Related]
55. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
Jacot W; Mollevi C; Fina F; Lopez-Crapez E; Martin PM; Colombo PE; Bibeau F; Romieu G; Lamy PJ
BMC Cancer; 2015 Dec; 15():986. PubMed ID: 26680641
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases.
Yan S; Jiao X; Zou H; Li K
Diagn Pathol; 2015 Jun; 10():62. PubMed ID: 26047809
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer.
Nieto Y; Nawaz F; Jones RB; Shpall EJ; Nawaz S
J Clin Oncol; 2007 Oct; 25(28):4405-13. PubMed ID: 17906204
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix.
Ueda A; Takasawa A; Akimoto T; Takasawa K; Aoyama T; Ino Y; Nojima M; Ono Y; Murata M; Osanai M; Hasegawa T; Saito T; Sawada N
PLoS One; 2017; 12(8):e0184123. PubMed ID: 28859123
[TBL] [Abstract][Full Text] [Related]
60. Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast.
Wang J; Zhang X; He J; Yang M; Tang J; Li X; Tang H; Xie X
Med Oncol; 2014 Sep; 31(9):172. PubMed ID: 25119504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
